Insmed (INSM) – Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of Insmed (NASDAQ: INSM) recently:

• 5/13/2026 – Insmed had its price target lowered by Truist Financial Corporation from $205.00 to $185.00. They now have a “buy” rating on the stock.
• 5/8/2026 – Insmed had its “buy” rating reaffirmed by HC Wainwright.
• 5/8/2026 – Insmed had its price target lowered by Guggenheim from $230.00 to $226.00. They now have a “buy” rating on the stock.
• 5/8/2026 – Insmed had its price target lowered by Royal Bank Of Canada from $220.00 to $205.00. They now have an “outperform” rating on the stock.
• 5/8/2026 – Insmed had its price target lowered by Wells Fargo & Company from $177.00 to $160.00. They now have an “overweight” rating on the stock.
• 4/21/2026 – Insmed had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 4/17/2026 – Insmed had its “buy” rating reaffirmed by Roth Mkm. They now have a $212.00 price target on the stock.
• 4/16/2026 – Insmed had its “buy” rating reaffirmed by Guggenheim. They now have a $230.00 price target on the stock.
• 4/14/2026 – Insmed had its price target raised by Royal Bank Of Canada from $212.00 to $216.00. They now have an “outperform” rating on the stock.
• 4/10/2026 – Insmed is now covered by Raymond James Financial, Inc.. They set an “outperform” rating and a $200.00 price target on the stock.
• 4/9/2026 – Insmed is now covered by Raymond James Financial, Inc.. They set a “moderate buy” rating on the stock.
• 4/1/2026 – Insmed had its price target raised by Barclays PLC from $231.00 to $237.00. They now have an “overweight” rating on the stock.
• 3/30/2026 – Insmed was upgraded by Morgan Stanley from “equal weight” to “overweight”. They now have a $212.00 price target on the stock, up from $166.00.
• 3/26/2026 – Insmed had its price target raised by HC Wainwright from $230.00 to $245.00. They now have a “buy” rating on the stock.
• 3/25/2026 – Insmed had its price target raised by Mizuho from $204.00 to $206.00. They now have an “outperform” rating on the stock.
• 3/24/2026 – Insmed had its price target raised by Leerink Partners from $210.00 to $215.00. They now have an “outperform” rating on the stock.
• 3/24/2026 – Insmed had its price target raised by Stifel Nicolaus from $205.00 to $208.00. They now have a “buy” rating on the stock.
• 3/24/2026 – Insmed had its price target raised by Bank of America Corporation from $211.00 to $213.00. They now have a “buy” rating on the stock.
• 3/23/2026 – Insmed had its price target lowered by Wells Fargo & Company from $208.00 to $175.00. They now have an “overweight” rating on the stock.

Insider Activity at Insmed

In related news, CEO William Lewis sold 10,699 shares of the firm’s stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $143.97, for a total transaction of $1,540,335.03. Following the completion of the transaction, the chief executive officer directly owned 301,185 shares of the company’s stock, valued at approximately $43,361,604.45. This trade represents a 3.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Roger Adsett sold 88,060 shares of the firm’s stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $164.63, for a total value of $14,497,317.80. Following the transaction, the chief operating officer owned 106,810 shares of the company’s stock, valued at $17,584,130.30. This represents a 45.19% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 161,193 shares of company stock valued at $25,462,012. Corporate insiders own 2.10% of the company’s stock.

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.